A Dose-Ranging Study of the Novel Inhaled Dual PDE 3 and 4 Inhibitor Ensifentrine in Patients with COPD Receiving Maintenance Tiotropium Therapy

PURPOSE: Ensifentrine is an inhaled dual inhibitor of phosphodiesterase (PDE) 3 and 4 that has shown bronchodilatory effects and symptom improvement in clinical studies in patients with chronic obstructive pulmonary disease (COPD), and anti-inflammatory effects in healthy volunteers in a model of CO...

Descripción completa

Detalles Bibliográficos
Autores principales: Ferguson, Gary T, Kerwin, Edward M, Rheault, Tara, Bengtsson, Thomas, Rickard, Kathleen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8075181/
https://www.ncbi.nlm.nih.gov/pubmed/33911859
http://dx.doi.org/10.2147/COPD.S307160

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8075181/
https://www.ncbi.nlm.nih.gov/pubmed/33911859
http://dx.doi.org/10.2147/COPD.S307160

Ejemplares similares